<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03640390</url>
  </required_header>
  <id_info>
    <org_study_id>N-112-2017</org_study_id>
    <nct_id>NCT03640390</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Magnesium Sulfate Infusion During Spinal Anesthesia</brief_title>
  <official_title>Dexmedetomidine Versus Magnesium Sulfate Infusion During Spinal Anesthesia for Lower Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this work is to compare the hemodynamic and analgesic properties of
      Dexmedetomidine and Magnesium sulphate infusion in lower abdominal surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexmedetomidine is a relatively new alpha 2 adrenergic receptor agonist with a higher α2/α1
      selectivity ratio of 1620:1 that provides analgesic and anesthetic effects . Dexmedetomidine
      has various clinical uses in anesthesia such as sedation, and prolongation of the duration of
      postoperative analgesia when used as an adjuvant through intrathecal, epidural, or
      intravenous routes.

      Magnesium sulphate is another commonly used drug in anesthesia. Magnesium sulphate suppresses
      nociceptive impulses through inhibition of voltage-gated calcium channels and through
      antagonism of the N-methyl D-aspartate (NMDA) receptors.

      Although both drugs were reported to prolong the duration of spinal anesthesia, no studies to
      the best of our knowledge had compared the analgesic and hemodynamic profile of both drugs
      when used as intravenously during spinal anesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Actual">September 10, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>Duration of analgesia after the operation defined as the time till the first analgesic request by the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>6 hours</time_frame>
    <description>Systolic blood pressure measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>6 hours</time_frame>
    <description>Diastolic blood pressure measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>6 hours</time_frame>
    <description>The number of heart beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of sensory block</measure>
    <time_frame>30 minutes after spinal anesthesia</time_frame>
    <description>The time needed to have complete sensory block after spinal anesthesia measured in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of motor block</measure>
    <time_frame>30 minutes after spinal anesthesia</time_frame>
    <description>The time needed to have complete motor block after spinal anesthesia measured in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of motor block</measure>
    <time_frame>12 hours</time_frame>
    <description>The time needed for recovery of motor motor after spinal anesthesia measured in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramsay Sedation Scale</measure>
    <time_frame>12 hours after spinal anesthesia</time_frame>
    <description>A scale used for assessment of sedation level ranges from 1 (combative) to 6 (unarousable)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium Sulphate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive Magnesium Sulphate infusion at a rate of 15 mg/Kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive normal saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>This group will receive Dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour.</description>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulphate</intervention_name>
    <description>This group will receive Magnesium sulphate infusion at a rate of 15 mg/Kg/hour</description>
    <arm_group_label>Magnesium Sulphate group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>This group will receive normal saline infusion</description>
    <arm_group_label>Saline group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients aged between 18 and 65 years.

          -  Scheduled for lower abdominal surgery.

        Exclusion Criteria:

          -  Systolic blood pressure less than 100 mmHg

          -  Coagulation disorders

          -  History of heart failure

          -  Mitral or Aortic stenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inas Farouk, Lecturer</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer of anesthesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Hasanin</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

